Loading
ThyraMIR v2 is a test from Interpace Biosciences that measures small RNA molecules in a thyroid nodule sample to help judge how likely it is to be cancer.
ThyraMIR v2 is Interpace Biosciences' microRNA-based endocrine cancer test, used with ThyGeNEXT on indeterminate thyroid nodules. Interpace reports that Labcorp was the largest customer for the pair in 2025 and the first half of 2026.
An algorithmic, pairwise microRNA expression analysis that refines the malignancy risk of an indeterminate thyroid nodule when combined with the ThyGeNEXT mutation panel, as described by Interpace Biosciences.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ThyraMIR v2" OR ABSTRACT:"ThyraMIR v2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ThyraMIR v2, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/